Trial Profile
Comparison of trastuzumab plus capecitabine combination therapy (HX therapy) and lapatinib plus capecitabine combination therapy (LX therapy) in HER2 positive metastatic or unresectable locally advanced breast cancer with history of trastuzumab and taxane anticancer drugs Randomized comparison II Exploratory study of effect predictors in phase test
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Trastuzumab
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms ELTOP study
- 10 Dec 2016 Status changed from active, no longer recruiting to completed, according to results presente at the 39th Annual San Antonio Breast Cancer Symposium..
- 08 Jan 2015 New trial record
- 13 Feb 2014 Planned number of patients changed from 170 to 110 as reported by University Hospital Medical Information Network - Japan.